Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 50 of 456 for:    Inherited Bleeding Disorder

China Obstetrics Alliance Cohort Study (COACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03038555
Recruitment Status : Enrolling by invitation
First Posted : January 31, 2017
Last Update Posted : January 31, 2017
Sponsor:
Collaborators:
Obstetrics & Gynecology Hospital of Fudan University
Tongji Medical College of Huazhong University of Science & Technology
Xinjiang Maternity & Children Health Care Hospital
Shandong Provincial Hospital
Information provided by (Responsible Party):
Dunjin Chen, The Third Affiliated Hospital of Guangzhou Medical University

Brief Summary:

Preeclampsia (PE) is one of a common type of hypertensive disorder complicating pregnancy (HDCP). It is a class of clinical syndromes which shows relevant symptoms, hypertension and proteinuria after 20 weeks pregnant as main characteristic, and may accompany with fetal anomaly and systemic multi-system organs damage. Several complications, such as eclamptic seizures, coma, intracranial hemorrhage (ICH), cardiac failure, pneumonedema, hepatic failure, kidney failure, placental abruption and disseminated intravascular coagulation (DIC), may be threat to the life of the mother as well as fetal. Thus, the disease is one of the core issues that cause the maternal and perinatal death. Morbidity of PE is approximately 3% to 5%. Morbidity has significant differences between different populations. According to the data, from 1995 to 2004, HDCP morbidity in four hospitals in Guangzhou was 5.78%, and in the HDCP, mild preeclampsia and severe preeclampsia were accounted for 72.22% and 27.78% respectively. Meanwhile, HDCP morbidity decreased from 9.4% (1984 to 1989) to 5.57% (1989 to 1998).

In 1996, the American Congress of Obstetricians and Gynecologists (ACOG) gave new classification of HDCP based on the characteristic of disease symptoms, divide into five groups; gestational hypertension, preeclampsia, eclampsia, chronic hypertension complicated with preeclampsia and chronic hypertension. The pathogenesis of PE remains unclear so far. The frequent sight is that PE caused by multiple reactions by a number of factors affect. Physiologically, mainly altered of PE is increased blood viscosity and systemic vascular spasm which cause hypoxic-ischemic of multiple key organs, such as the placenta, kidney, liver and brain. The research theory includes abnormal trophoblast invasion, immune response abnormal or increase, genetic susceptibility, coagulation disorders or thrombophilia, abnormal angiogenesis, endothelial cell damage, abnormal levels of carbonic oxide, increase of oxygen radical, abnormal metabolism of calcium ion, heterotrophia and so on. However, there are numbers of epidemiologic study have analyzed high risk factor of PE which provides significant medical evidence of prevention, early diagnosis and early treatment for PE, there is only little study focus on susceptibility gene and pathogenic genetic variation. Nowadays, there are numerous clinical phenotype are considered to exist, different phenotype gives different inheritance and epigenetics. Thus, our group will examine the onset of type and characteristics of PE by a retrospective cohort study to discuss if susceptibility gene and pathogenic genetic variation were existing in PE patients, also to find the relativity between clinical phenotype and genotype. Moreover, this study is trying to reach the effect of PE on the patients' health as well as their children. Thus, can predict the health status of PE patients and their children, and so can prevent (avoid or delay) of the patients from late complications and disease in their children.


Condition or disease
Preeclampsia

Detailed Description:
  1. All female staff that works, examination and delivery in the Third Affiliated Hospital of Guangzhou Medical University from Dec 1995 to Dec 2016 should be in the cohort. Collect all information; include clinical examination and medical examination, science the subject work in the hospital. Collect the perinatal data; include obstetric information, past medical history, family history and so on. Build the database and analyze the relative factor.
  2. From all subjects, choose subjects that have got PE before as the experimental group. Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease. Store the blood samples (serum, blood and plasma) of both the experimental group and control group and their children. Compare the differences of functional parameter between two groups both before and after delivery, which include blood pressure, blood glucose and blood lipids. Moreover, compare the function of heart, liver and kidney and genetic material (DNA and RNA).
  3. Diagnostic standard of PE refer to People's Medical Publishing House <Obstetrics and Gynecology> 8th edition. Confirm the diagnostic standard of HDCP and relative disease include PE will make sure the veracity and uniformity of diagnosis.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 900 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Study of Prevention and Intervention Strategy of Gestational Diseases Based on Cohort
Actual Study Start Date : January 1, 2017
Estimated Primary Completion Date : January 1, 2019
Estimated Study Completion Date : January 1, 2022

Resource links provided by the National Library of Medicine


Group/Cohort
Disease group (subject to strategy)
Choose subjects that have ever got PE before as the diseases group.
Control group
Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.



Primary Outcome Measures :
  1. track the difference between preeclampsia and normal [ Time Frame: 2 years ]
    Our main judgement criterion allowing to distinguish patients with preeclampsia from those without disease


Biospecimen Retention:   Samples With DNA

Store the blood samples (serum, blood and plasma) of both the experimental group and control group and their children.

These additional samples were be centrifuged and treated and stored in a collection of biological samples of total serum and plasma and blood at the Biobank of The Third Affiliated Hospital of Guangzhou Medical University at -80 ° C



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Sampling Method:   Non-Probability Sample
Study Population
Choose subjects that have got PE before as the experimental group. Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.
Criteria

Inclusion Criteria:

  • Choose subjects that have got PE before as the experimental group. Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1.

Exclusion Criteria:

  • Subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03038555


Locations
Layout table for location information
China, Guangdong
Guangzhou Institute of Obstetrics & Gynecology
Guangzhou, Guangdong, China, 510150
China, Hubei
Tongji Medical College Huazhong University of Science & Technology
Wuhan, Hubei, China, 430030
China, Shandong
Shandong Provincial Hospital
Jinan Shi, Shandong, China
China, Xinjiang
Xinjiang Maternity & Children Health Care Hospital
Urumqi, Xinjiang, China, 96595
China
Obstetrics and Gynecology Hospital of Fudan University
Shanghai, China
Sponsors and Collaborators
The Third Affiliated Hospital of Guangzhou Medical University
Obstetrics & Gynecology Hospital of Fudan University
Tongji Medical College of Huazhong University of Science & Technology
Xinjiang Maternity & Children Health Care Hospital
Shandong Provincial Hospital

Layout table for additonal information
Responsible Party: Dunjin Chen, Guangzhou Institute of Obstetrics & Gynecology, The Third Affiliated Hospital of Guangzhou Medical University
ClinicalTrials.gov Identifier: NCT03038555     History of Changes
Other Study ID Numbers: 2016YFC1000405
First Posted: January 31, 2017    Key Record Dates
Last Update Posted: January 31, 2017
Last Verified: January 2017
Keywords provided by Dunjin Chen, The Third Affiliated Hospital of Guangzhou Medical University:
Medical staff
preeclampsia
cohort study
further effect
Additional relevant MeSH terms:
Layout table for MeSH terms
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications